NetraMark Delivers Transformational Quarter Of Execution
Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award...
Clinical Trial
NetraMark Delivers Transformational Quarter Of Execution
Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award...
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the...
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the...
Beacon Therapeutics to Present at the 44th Annual JP Morgan Healthcare Conference
LONDON and CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a...
Beacon Therapeutics to Present at the 44th Annual JP Morgan Healthcare Conference
LONDON and CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a...
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027...
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027...
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for...
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for...
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator,...
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator,...
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple...
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple...
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE)...
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE)...
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve...
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve...
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...